Nuvation Bio [NUVB] vs Dyne Therapeutics [DYN] Detailed Stock Comparison

Nuvation Bio

NYSE
Loading...

Dyne Therapeutics

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Nuvation Bio wins in 8 metrics, Dyne Therapeutics wins in 7 metrics, with 0 ties. Nuvation Bio appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricNuvation BioDyne TherapeuticsBetter
P/E Ratio (TTM)-1.49-3.90Dyne Therapeutics
Price-to-Book Ratio2.882.63Dyne Therapeutics
Debt-to-Equity Ratio15.4921.19Nuvation Bio
PEG Ratio0.02-0.10Dyne Therapeutics
EV/EBITDA2.61-2.98Dyne Therapeutics
Profit Margin (TTM)10.10%0.00%Nuvation Bio
Operating Margin (TTM)-1,315.72%0.00%Dyne Therapeutics
Return on Equity-44.84%-61.32%Nuvation Bio
Return on Assets (TTM)20.17%-35.45%Nuvation Bio
Free Cash Flow (TTM)$-130.58M$-294.75MNuvation Bio
1-Year Return2.95%-61.39%Nuvation Bio
Price-to-Sales Ratio (TTM)74.87N/AN/A
Enterprise Value$524.78M$1.31BDyne Therapeutics
EV/Revenue Ratio36.56N/AN/A
Gross Profit Margin (TTM)46.70%N/AN/A
Revenue per Share (TTM)$0$0Nuvation Bio
Earnings per Share (Diluted)$-0.38$-3.88Nuvation Bio
Beta (Stock Volatility)1.371.10Dyne Therapeutics
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Nuvation Bio vs Dyne Therapeutics Stock Performance Analysis

Loading Price Chart...

Nuvation Bio
Dyne Therapeutics
Nuvation Bio Stock Overview | Dyne Therapeutics Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nuvation Bio-6.27%-19.49%35.34%73.48%40.18%21.24%
Dyne Therapeutics-0.19%-7.52%13.17%-9.06%6.39%-48.35%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nuvation Bio2.95%38.33%-71.45%-68.44%-68.44%-68.44%
Dyne Therapeutics-61.39%-3.66%-42.32%-42.32%-42.32%-42.32%

News Based Sentiment: Nuvation Bio vs Dyne Therapeutics

Nuvation Bio

News based Sentiment: POSITIVE

Nuvation Bio demonstrated strong early commercial traction with IBTROZI™ in Q2 2025, coupled with active investor engagement and a potential financing deal for taletrectinib. While some analyst concerns exist, the overall narrative is positive, supported by insider buying and bullish market signals.

View Nuvation Bio News Sentiment Analysis

Dyne Therapeutics

News based Sentiment: POSITIVE

September was a significant month for Dyne Therapeutics, marked by positive clinical data for their DM1 program, active investor engagement at key conferences, and a clear timeline for upcoming data readouts and BLA submissions. These developments strengthen the investment case and suggest the company is progressing towards potential commercialization, though risks related to trial outcomes and regulatory approval remain.

View Dyne Therapeutics News Sentiment Analysis

Performance & Financial Health Analysis: Nuvation Bio vs Dyne Therapeutics

MetricNUVBDYN
Market Information
Market Cap i$1.07B$1.87B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i8,443,2602,080,960
90 Day Avg. Volume i6,001,9972,782,247
Last Close$3.14$13.15
52 Week Range$1.54 - $4.09$6.36 - $37.08
% from 52W High-23.23%-64.54%
All-Time High$15.23 (May 24, 2021)$47.45 (Aug 19, 2024)
% from All-Time High-79.38%-72.29%
Growth Metrics
Quarterly Revenue Growth2.37%N/A
Quarterly Earnings Growth2.37%N/A
Financial Health
Profit Margin (TTM) i0.10%0.00%
Operating Margin (TTM) i-13.16%0.00%
Return on Equity (TTM) i-0.45%-0.61%
Debt to Equity (MRQ) i15.4921.19
Cash & Liquidity
Book Value per Share (MRQ)$1.09$5.00
Cash per Share (MRQ)$1.78$4.81
Operating Cash Flow (TTM) i$-168,192,000$-359,560,000
Levered Free Cash Flow (TTM) i$179.17M$-222,398,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Nuvation Bio vs Dyne Therapeutics

MetricNUVBDYN
Price Ratios
P/E Ratio (TTM) i-1.49-3.90
Forward P/E i-4.98-4.16
PEG Ratio i0.02-0.10
Price to Sales (TTM) i74.87N/A
Price to Book (MRQ) i2.882.63
Market Capitalization
Market Capitalization i$1.07B$1.87B
Enterprise Value i$524.78M$1.31B
Enterprise Value Metrics
Enterprise to Revenue i36.56N/A
Enterprise to EBITDA i2.61-2.98
Risk & Other Metrics
Beta i1.371.10
Book Value per Share (MRQ) i$1.09$5.00

Financial Statements Comparison: Nuvation Bio vs Dyne Therapeutics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)NUVBDYN
Revenue/Sales i$4.83M$0
Cost of Goods Sold i$2.58MN/A
Gross Profit i$2.26MN/A
Research & Development i$27.36M$99.24M
Operating Income (EBIT) i$-63.59M$-115.79M
EBITDA i$-58.65M$-110.26M
Pre-Tax Income i$-59.01M$-110.86M
Income Tax i$0N/A
Net Income (Profit) i$-59.01M$-110.86M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)NUVBDYN
Cash & Equivalents i$47.98M$472.26M
Total Current Assets i$475.57M$689.50M
Total Current Liabilities i$52.77M$33.88M
Long-Term Debt i$3.84M$18.22M
Total Shareholders Equity i$419.46M$668.97M
Retained Earnings i$-963.98M$-1.07B
Property, Plant & Equipment i$1.53M$34.19M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)NUVBDYN
Operating Cash Flow i$-32.06M$-110.37M
Capital Expenditures i$-72,000$-981,000
Free Cash Flow i$-42.70M$-106.87M
Debt Repayment i$-534,000N/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNUVBDYN
Shares Short i68.13M16.04M
Short Ratio i15.085.24
Short % of Float i0.32%0.13%
Average Daily Volume (10 Day) i8,443,2602,080,960
Average Daily Volume (90 Day) i6,001,9972,782,247
Shares Outstanding i337.84M102.32M
Float Shares i231.05M122.63M
% Held by Insiders i0.19%0.00%
% Held by Institutions i0.67%0.95%

Dividend Analysis & Yield Comparison: Nuvation Bio vs Dyne Therapeutics

MetricNUVBDYN
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A